Xilio Therapeutics Reports Q2 2026 Financial Results

What Happened Xilio Therapeutics, Inc. (XLO) announced its financial results and business highlights for the quarter ended June 30, 2026 in a press release dated August 12, 2026. The press release is furnished with this Form 8-K as Exhibit 99.1 and summarizes the company’s quarterly performance.

Key Details

• Announcement date: August 12, 2026; quarter covered: ended June 30, 2026.
• The full press release is attached to the 8-K as Exhibit 99.1 (furnished, not filed).
• The filing specifically states the information is furnished under Item 2.02 and is not being “filed” for Section 18 liability purposes or automatically incorporated by reference into other filings unless expressly stated.

Why It Matters This 8-K signals that Xilio has released its quarterly earnings and related business updates; investors should read Exhibit 99.1 (the press release) for the specific earnings, revenue, cash position, and any guidance or program updates. Because the exhibit is furnished rather than filed, the company limits certain formal SEC liabilities — but the release still contains the company’s official quarterly results and highlights that can affect investor decisions.